{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-056937","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.499370+00:00","generated_at":"2026-06-05T04:49:46.081001+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acrivon appoints Santhosh Palani, Ph.D., CFA, to board of directors effective March 4, 2024","bullets":["Dr. Palani appointed board member effective March 4, 2024; receives 32,500 share option grant vesting over 3 years.","He brings experience as former investment partner at PFM Health Sciences and prior roles at NEA, Cowen, Pfizer, Takeda.","No transactions requiring disclosure under Item 404(a); standard indemnification agreement entered."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-056937","json":"https://secwatch.observer/filing/0001193125-24-056937.json","markdown":"https://secwatch.observer/filing/0001193125-24-056937.md","text":"https://secwatch.observer/filing/0001193125-24-056937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312524056937/0001193125-24-056937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312524056937/d791106d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:49:46.081001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0804cd93f","claim":"Santhosh Palani, Ph.D., CFA was appointed as director at Acrivon Therapeutics, Inc..","evidence_excerpt":"On March 1, 2024, the Board of Directors of Acrivon Therapeutics, Inc. (the “Company”) appointed Santhosh Palani, Ph.D., CFA, as a director of the Company, effective March 4, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312524056937/0001193125-24-056937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}